The European Infrastructure of Open Screening Platforms for Chemical Biology (EU-OPENSCREEN) is a distributed Research Infrastructure that develops novel small chemical compounds which elicit specific biological responses on organisms, cells or cellular components. EU-OPENSCREEN enables scientists to use compound screening methods to validate novel therapeutic targets and support basic mechanistic studies addressing fundamental questions in cellular physiology, across domain systems, using the methods of chemical biology. EUOPENSCREEN is a cost-effective solution to address the need of the broad scientific community providing access to Europe’s leading screening platforms and chemistry groups, a jointly used compound collection and operating an open-access database accessible on a global basis.

In the ESFRI Roadmap since 2008, EU-OPENSCREEN has established the European Research Infrastructure Consortium (ERIC) in 2018. As of November 2021, EU-OPENSCREEN ERIS is supported by eight Member States hosting 23 Partners Sites which offer access to academic high-throughput screening compounds facilities – jointly comprising up to 140.000 commercial and proprietary compounds – and medicinal chemistry services. EU-OPENSCREEN supports all stages of a tool development project, including assay adaptation, high-throughput screening, and chemical optimisation of the ‘hit’ compounds. All generated tool compounds and data are made available in an open access database with the possibility to request a grace period of up to three years to allow for data deposition after submitting a patent application.